Elevated serum trigylcerides and low high-density lipoprotein (HDL) cholesterol are part of a
metabolic syndrome that is increasingly being recognized as an important risk factor for
cardiovascular disease. Several classes of pharmacological agents including fibrates, niacin
and statins, can modify the triglyceride–HDL axis. Fibrates in particular have recently been
shown in clinical trials not only to increase HDL, but also to reduce cardiovascular mortality
in secondary prevention. More research is needed to further define the role of fibrates when …